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Many palliative care doctors feel that patients receiving 
palliative care in the community are disadvantaged 
in accessing drugs because the Pharmaceutical 
Benefits Scheme (PBS) constrains them. Members of 
the Australian and New Zealand Society for Palliative 
Medicine (ANZSPM) started to advocate to redress 
this. Barriers to changing the PBS regulations were: 
some drugs on the list require Therapeutics Goods 
Administration approval for palliative care indications; 
others needed evidence of effectiveness, cost 
effectiveness and clinical place in therapy for PBS listing; 
and these drugs would require an industry sponsor 
to fund and take on responsibility for the application 
and subsequent use, as required by Australian law – a 
problem as many drugs were out of patent. 
	
As	 a	 way	 forward,	 a	 Joint	Therapeutics	 Committee	
of	 Palliative	 Care	Australia,	 ANZSPM,	 and	 the	 Clinical	
Oncological	Society	of	Australia	 formed	 to	generate	a	 list	
of	 essential	 drugs	 for	 palliative	 care.	One	had	 previously	
been	generated	 from	a	world	survey	sent	 to	50	palliative	
care	doctors	 in	25	different	countries	 (including	Australia),	
and	a	 list	of	what	was	 thought	 the	 ‘20	essential	drugs	 in	
palliative	care’	published.1	
	 We	decided	to	survey	palliative	care	doctors	in	Australia	
to	 compile	 a	 similar	 list	 of	 essential	 drugs,	 and	 also	 to	
assess	 the	 level	 of	 evidence	 for	 them,	 setting	out	which	
were	available	through	the	PBS.
Method
We	 surveyed	members	 of	ANZSPM,	 asking	 them	what	
they	 thought	 were	 essential	 drugs	 for	 palliative	 care.	
The	 questionnaire	 used	 a	 list	 of	 the	 22	most	 frequently	
encountered	 symptoms	derived	 from	 the	 literature,	 ‘pain’	
occupying	 three	 of	 these.	 Respondents	 could	 list	 up	 to	
five	 individual	drugs	 for	each	symptom,	 together	with	 their	
estimated	 level	of	evidence	 for	 the	drug	 for	 that	 indication,	
using	a	 ranking	of	 the	evidence	 (Table 1).	This	differs	 from	
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 RESEARCH
Table 1. Levels of evidence used in the questionnaire
Level 1	 	Evidence	from	systematic	review	of	all	relevant	randomised	controlled	trials
Level 2	 	Evidence	from	at	least	one	properly	designed	randomised	controlled	trial
Level 3	 	Evidence	from	nonrandomised	controlled	trials,	cohort	studies,	case	control	studies	
Level 4	 	Evidence	from	case	reports/expert	opinion	
Level 5	 Unknown	to	respondent	what	level	of	evidence	exists	
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current	National	Health	 and	Medical	 Research	
Council	 (NHMRC)	 guidelines2	 in	 retaining	 the	
expert	 opinion	 no	 longer	 included	 in	NHMRC	
guidelines.	While	 these	 levels	 have	 been	used	
throughout	the	article	for	consistency,	where	the	
only	evidence	available	 is	expert	opinion,	 that	 is	
denoted	‘4E’.	
	 The	 questionnaire	was	 hand	 delivered	 to	
registrants	 at	 a	 biennial	 scientific	 committee	of	
ANZSPM	held	in	Geelong	(Victoria)	in	September	
2000	 and	 in	 addition,	 mailed	 to	 all	 other	
members	not	present.	
	 The	Hunter	Area	Research	Ethics	Committee	
gave	ethics	approval	for	this	study.	
Results
Out	of	 350	questionnaires,	 102	were	 returned.	
Two	were	 excluded	 because	 the	 address	was	
unknown,	 giving	 a	 response	 rate	 of	 100/350	
(29%).	Median	age	was	46	years	 (range	28–70),	
and	median	 time	since	graduation	was	21	years	
(range	5–49).	Most	respondent's	(58%)	main	area	
of	practice	was	palliative	medicine,	while	the	rest	
were	mostly	general	practitioners	with	experience	
in	palliative	care.
	 The	first	ranked	drug	for	selected	symptoms,	
PBS	 availability,	 and	 level	 of	 evidence	 at	 the	
Table 2. Palliative symptoms, with the drug nominated as ‘essential’ for that symptom, by symptom control, PBS subsidy, and perceived  
and actual evidence of benefit
    PBS subsidy     
	 	 	 	 at time of Level of  
	 	 	 % of respondents survey evidence
   nominating this (September nominated by % Level of
Palliative symptom  Drug drug as first rank 2000) respondents responding evidence Reference
Pain	using	opioid	analgesics	 Morphine	 98	 Yes		 1	 43	 2	 4	 	
	 	 	 	 	 2	 12	 	
	 	 	 	 	 3	 9	 	
	 	 	 	 	 4	 9
	 	 	 	 	 5	 27
Pain	using	nonopioid	analgesics	 Paracetamol	 88	 Yes	 1	 43	 1	 5
	 	 	 	 	 2		 5
	 	 	 	 	 3	 11
	 	 	 	 	 4	 9
	 	 	 	 	 5	 32
Pain	using	adjuvant	analgesics	 Valproate	 61	 Yes	 1	 8	 1	 6
	 	 	 	 	 2	 18
	 	 	 	 	 3	 22
	 	 	 	 	 4	 12
	 	 	 	 	 5	 40
Dyspnoea	 Morphine	 94	 No	 1	 9	 2	 7
	 	 	 	 	 2	 18
	 	 	 	 	 3	 26
	 	 	 	 	 4	 15
	 	 	 	 	 5	 31
End	stage	respiratory		 Hyoscine		 86	 No	 1	 4	 4	 8
reflexes	(grunting,	secretions)	 Hydrobromide	 	 	 2	 6
	 	 	 	 	 3	 22
	 	 	 	 	 4	 31
	 	 	 	 	 5	 37
Terminal	restlessness	 Midazolam	 81	 No	 1	 5	 4	 9
	 	 	 	 	 2	 8
	 	 	 	 	 3	 15
	 	 	 	 	 4	 31
	 	 	 	 	 5	 41
Anorexia	 Dexamethasone	 69	 Yes		 1	 6	 2	 10
	 	 	 	 	 2	 20
	 	 	 	 	 3	 20
	 	 	 	 	 4	 19
	 	 	 	 	 5	 35
Nausea	 Metoclopramide	 86	 Yes		 1	 19	 3	 11
	 	 	 	 	 2	 14
	 	 	 	 	 3	 12
	 	 	 	 	 4	 11
	 	 	 	 	 5	 45
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time	of	 the	survey	are	 listed	 in	Table 2.	Table 2	
shows	a	60%	agreement	between	 respondents	
in	regards	to	the	number	one	medication	used	in	
each	category,	apart	from	anxiety,	depression,	dry	
mouth,	and	constipation.	
	 The	20	most	frequently	nominated	drugs	and	
level	of	evidence	are	shown	in	Table 3.1
Discussion 
The	response	rate	of	the	survey	was	low,	therefore	
we	 cannot	 be	 sure	 this	 represents	Australian	
palliative	 care	 doctors.	 Nevertheless,	 a	 broad	
spectrum	of	 palliative	 care	 doctors	 responded	
and	our	 findings	were	similar	 to	 the	 international	
survey.1	There	were	 differences	 among	 the	 20	
essential	drugs	with	only	10	common	to	both	lists	
(the	top	eight,	followed	by	diazepam	and	fentanyl).	
There	are	many	possible	explanations,	 including	
different	 availability	 and	 formulations,	 costs	 and	
different	preferences	 (perhaps	based	on	 clinical	
experience	 rather	 than	evidence).	Laxatives	such	
as	lactulose	are	commonly	prescribed	worldwide,	
while	 in	Australia,	 docusate	 and	 senna	 is	most	
commonly	prescribed.	There	 is	no	evidence	 that	
adding	docusate	 to	senna	provides	benefit.	Any	
difference	between	lactulose	and	senna	appears	to	
be	minimal	in	the	small	amount	of	data	available.3
	 There	 seems	 to	 be	 a	 relatively	 low	 level	 of	
evidence	 for	 some	 important	 medications	 in	
palliative	care	(eg.	midazolam)	although	the	majority	
of	first	ranked	drugs	have	at	least	level	2	evidence.	
Apart	from	the	most	frequently	used	medications,	
there	 was	 a	 large	 discrepancy	 between	 the	
respondents’	belief	about	the	available	evidence	and	
what	is	actually	available.	For	example	paracetamol	
for	pain,	where	 level	1	evidence	 is	available,	but	
the	majority	 of	 respondents	 rated	 evidence	 as	
levels	3–5,	while	more	 than	one	 in	3	 respondents	
thought	morphine	only	had	level	4	or	5	evidence	for	
analgesia,	whereas	 the	evidence	 is	 level	2.	About	
a	 third	 thought	 there	was	 level	1–3	evidence	 for	
hyoscine	hydrobromide	 (level	 4)	 and	midazolam	
(level	4).
	 We	have	used	these	lists	to	facilitate	a	process	
to	 increase	 their	PBS	 listing	with	a	group	made	
up	of	the	medical	profession	and	the	Rural	Health	
and	 Palliative	 Care	Branch	 of	 the	Department	
of	 Health	 and	Ageing	 in	 association	with	 the	
Australian	government.	This	has	lead	to	a	section	
in	 the	PBS	specifically	 for	palliative	care	with	an	
initial	list	of	approved	drugs.	
	 For	many	widely	used	drugs	the	best	level	of	
evidence	is	not	sufficient	to	justify	further	subsidy.	
Reasons	may	be	 that	studies	have	not	yet	been	
undertaken	–	we	should	address	this.
Implications for general practice
•	Access	to	drugs	for	palliative	care	is	harder	
in	 the	 community	 (through	 the	PBS)	 than	
in	hospital.
•	A	survey	of	palliative	care	doctors	produced	
a	list	of	drugs	they	thought	essential.
•	Their	perception	of	the	evidence	for	their	use	
was	variable.
•	Collaborative	work	has	led	to	the	creation	of	
the	first	ever	section	in	the	PBS	for	a	specific	
patient	population.	
•	There	 is	 a	 need	 for	 high	quality	 studies	 to	
justify	PBS	listing	of	palliative	care	drugs.
Table 2. (continued) Palliative symptoms, with the drug nominated as ‘essential’ for that symptom, by symptom control, PBS subsidy,  
and perceived and actual evidence of benefit
    PBS subsidy     
	 	 	 	 at time of Level of  
	 	 	 % of respondents survey evidence
   nominating this (September nominated by % Level of
Palliative symptom  Drug drug as first rank 2000) respondents responding evidence Reference
Constipation	 Docusate		 58	 No	 1	 9	 4E	 12
	 	 and	senna	 	 	 2	 12
	 	 	 	 	 3	 14
	 	 	 	 	 4	 17
	 	 	 	 	 5	 48
Dry	mouth	 Artificial		 39	 No	 1	 –	 2	 13
	 	 saliva	 	 	 2	 9
	 	 	 	 	 3	 15
	 	 	 	 	 4	 6
	 	 	 	 	 5	 70
Delirium	 Haloperidol	 84	 Yes		 1	 21	 2	 14
	 	 	 	 	 2	 16
	 	 	 	 	 3	 13
	 	 	 	 	 4	 11
	 	 	 	 	 5	 39
Depression	 Sertraline	 40	 Yes	 1	 25	 2	 15
	 	 	 	 	 2	 17
	 	 	 	 	 3	 7
	 	 	 	 	 4	 3
	 	 	 	 	 5	 48
Anxiety	 Diazepam	 52	 Yes		 1	 23	 2	 16
	 	 	 	 	 2	 11
	 	 	 	 	 3	 6
	 	 	 	 	 4	 6
	 	 	 	 	 5	 54
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Table 3. Ranking of ‘essential’ drug, compared with those of a previous world survey
Rank Drug Main palliative Rank number of a  Highest level Current PBS listing 
  care indication previous (world) of evidence (December 2005) 
   survey1
1	 Morphine	 Pain	 1,*	5*	 1		17	 Yes
2	 Haloperidol	 Delirium	 2	 2		14	 Yes
3	 Dexamethasone	 Anorexia/cachexia	 4	 2		10	 Yes
4	 Midazolam	 Terminal	restlessness	 7	 4		9	 No
5	 Metoclopramide	 Nausea/vomiting	 3	 1		18	 Yes
6	 Clonazepam	 Terminal	restlessness	 15	 4E	 12	 Yes
7	 Paracetamol	 Pain	 9	 1		5	 Yes
8	 Amitryptiline	 Neuropathic	pain	 6	 1		19	 Yes
9	 Pamidronate	 Hypercalcaemia	 	 2		20	 Yes
10	 Cyclizine	 Nausea/vomiting	 	 4E		12	 No
11	 Hyoscine	hydrobromide	 Excess	oropharyngeal	secretions	 	 3		21	 No
12	 Diazepam	 Anxiety	 17	 2		16	 Yes
13	 Lorazepam	 Anxiety	 	 2		22	 No
14	 Omeprazole	 Dyspepsia	 	 1		23	 Yes
15	 Chlorpromazine	 Delirium	 	 2		14	 Yes
16	 Fentanyla	 Pain	 12	 1		24	 Yes
17	 Spironolactone	 Ascites	 	 4		25	 Yes
18	 Ranitidine	 Dyspepsia	 	 1		26	 Yes
19	 Promethazine	 Nausea/itch	 	 4E		12	 Yes
20	 Frusemide	 Ascites	 	 4		27	 Yes
a	=	injectable	fentanyl	not	available	on	the	PBS		*	=	normal	release		+	=	sustained	release
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